After a relatively quiet few months for drug developer InterMune
In advance of a major liver-disease conference in November, InterMune and development partner Roche released data and abstracts for protease inhibitior ITMN-191 from several preclinical and phase 1 studies of the drug.
Unlike some of ITMN-191's potential rivals, testing's still in too early a stage to draw definitive conclusions about its efficacy against competitors. That said, its initial results seem roughly comparable to other drugs' preliminary performance. In one 14-day study of patients who'd failed other hepatitis C therapies, ITMN-191 lowered the levels of hepatitis C in patients to roughly the same average level that Vertex's
In Wednesday's release, InterMune also included some preclinical data testing ITMN-191 with other Roche hepatitis C compounds. Ironically, ITMN-191's future might depend as much on the success of one of Roche's hepatitis C partners as on its own.
Over the past several months, Vertex and Schering-Plough
If Roche's polymerase/protease inhibitor combinations work notably better (and no less safely) than Schering and Vertex's single-therapy approaches, ITMN-191 could become the protease inhibitor of choice for treating hep C. That will be particularly true if doctors display a preference for drugs proven in combination testing, rather than leaning toward Vertex or Schering's compounds.
Many potential hep C compounds that produced solid preclinical data, like ViroPharma
InterMune and Vertex are active picks of our Rule Breakers newsletter. You can check out all our other recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.